CEA cell adhesion molecule 5Genealiases: CD66e · CEA
Q-omics provides the consensus-scored CEACAM5 profile across patient tissues and cancer cell-line models. CEACAM5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CEACAM5 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, CEACAM5 RNA expression shows 14,082 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, HNSC, and BRCA as cancer lineages where CEACAM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEACAM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEACAM5 survival associations across molecular data types. CEACAM5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEACAM5 RNA expression–survival associations across cancer types. High CEACAM5 expression shows unfavorable associations in KIRC, KIRP, DLBC and SKCM, but favorable associations in HNSC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CEACAM5 RNA expression.
This table summarizes CEACAM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CEACAM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEACAM5 shows lower tumor expression in HNSC and higher tumor expression in LUAD, BRCA, PAAD, BLCA and UCEC. The HNSC box plot shows higher CEACAM5 RNA expression in normal versus tumor tissue (log2 FC = −2.846, t-test p < 0.001).
This table shows molecular features associated with CEACAM5 in patient tissues and cancer cell lines. In patient samples, CEACAM5 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CEACAM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
